Candel Therapeutics Reports $23 Million Quarterly Loss

The biotech company's third-quarter operating loss widened from a year earlier as it continues talks with the FDA on a prostate cancer treatment.

Updated on Nov. 13, 2026 in Biotech

Candel Therapeutics Reports $23 Million Quarterly Loss

Candel Therapeutics posted a third-quarter loss from operations of $23 million, or 28 cents a share, up from $13.2 million, or 21 cents a share, a year earlier. Shares fell 9% through market close Thursday and dropped a further 38% to $5.15 in after-hours trading.

Why it matters

The rise in operating expenses from $13.2 million to $23 million reflects spending as the company advances its lead candidate toward regulatory review. The outcome of ongoing dialogue with the FDA will determine the timing of its next filing for aglatimagene in prostate cancer.

The company reported an operating loss of $23 million, or 28 cents per share, against $13.2 million, or 21 cents per share, a year earlier, with operating expenses rising to $23 million from $13.2 million. Whether the planned biologics license application can proceed as scheduled has not been resolved, as it hinges on the FDA dialogue.

The players

Candel Therapeutics

A clinical-stage biotechnology company developing oncology therapies, including aglatimagene for prostate cancer, and listed on public markets.

U.S. Food and Drug Administration (FDA)

The federal agency responsible for reviewing and approving biologics license applications and other drugs sold in the United States.

The details

Candel Therapeutics disclosed the results in its third-quarter report on Thursday, November 12, 2026. The company said it is in ongoing dialogue with the FDA about a biologics license application for aglatimagene treatment in prostate cancer. Shares were up 49% year to date before Thursday's decline.

Timeline

  1. Thursday, November 12, 2026: Third-quarter results released and shares fell after hours.

  2. Middle of 2027: Planned submission of the biologics license application, depending on the FDA dialogue.

Tech Race

Candel's planned biologics license application follows the standard FDA pathway for novel biologic therapies under the Public Health Service Act, with its timing still dependent on ongoing agency dialogue. The company's spending increase places it among gene and viral-therapy developers racing to clear that same review process.

For patients with prostate cancer, the outcome of the FDA review will determine whether aglatimagene becomes a treatment option and when. Investors in the stock should note that the after-hours drop to $5.15 followed a 49% year-to-date gain.

The takeaway

Candel's spending increase is tied to a regulatory timeline that depends on FDA feedback, so the next meaningful milestone is the agency's response rather than the quarterly numbers themselves.

What happens next

Candel Therapeutics plans to submit the biologics license application for aglatimagene in the middle of 2027, depending on the outcome of its FDA dialogue.

Further reading

For more on the regulatory side of drug development, explore our Biotech coverage.